<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091619</url>
  </required_header>
  <id_info>
    <org_study_id>2016L10765-2</org_study_id>
    <nct_id>NCT05091619</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed</brief_title>
  <acronym>DTaP</acronym>
  <official_title>A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, immunogenicity，immune persistence and lot-to-lot&#xD;
      consistency of Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined&#xD;
      Vaccine, Adsorbed, (DTacP) including 2 parts:&#xD;
&#xD;
      PART 1 will evaluate the safety and immunogenicity of DTacP in health infants aged 2 months&#xD;
      and 3 months compared with an adsorption Tetanus-diphtheria-acellular Pertussis (DTaP)&#xD;
      Vaccine and Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated)&#xD;
      vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine (PENTAXIM)，compare the&#xD;
      safety and immunogenicity of DTacP with different immunization schedules, and observe the&#xD;
      immune persistence.&#xD;
&#xD;
      PART 2 will evaluate the lot-to-lot consistency of DTacP in health infants aged 3 months with&#xD;
      the 3-dose schedule of 3-4-5 month.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">September 22, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The seroconversion rate of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>1 month after Dose 3</time_frame>
    <description>seroconversion is defined as post-third dose antibody concentrations ≥ protective antibody concentration if pre-vaccination concentration is &lt; protective antibody concentration, or ≥ 4 x protective antibody concentration if pre-vaccination concentrations ≥ protective antibody concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>1 month after Dose 3</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions</measure>
    <time_frame>Day 7 post-each dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events</measure>
    <time_frame>Day 7 post-each dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events</measure>
    <time_frame>within 30 days post-each dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The seropositivity rate of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>Day 30 post-dose 3</time_frame>
    <description>Seropositivity is defined as post-3 dose antibody concentrations ≥ protective antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>before dose 4 at 18 months old(booster)</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seropositivity rate of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>before dose 4 at 18 months old(booster)</time_frame>
    <description>Seropositivity is defined as antibody concentrations ≥ protective antibody concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>Day 30 post-dose 4 at 18 months old(booster)</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seropositivity rate of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>Day 30 post-dose 4 at 18 months old(booster)</time_frame>
    <description>eropositivity is defined as antibody concentrations ≥ protective antibody concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentrations (GMCs) of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>12th month, 24th month, 36th month post-dose 4 , before 6 years old and day 30 post-dose 5</time_frame>
    <description>As measured at the central laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>The seropositivity rate of anti-pertussis toxoid , anti-filamentous hemagglutinin, anti-Pertactin, anti-diphtheria toxoid and anti-tetanic antibody</measure>
    <time_frame>12th month, 24th month, 36th month post-dose 4 , before 6 years old and day 30 post-dose 5</time_frame>
    <description>Seropositivity is defined as antibody concentrations ≥ protective antibody concentration</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">2898</enrollment>
  <condition>Whooping Cough</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects aged 2 months receive 3 doses of vaccines with a interval of 30 days for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 2 months receive 3 doses of vaccines with a interval of 2 months for primary immunization, and a booster dose at 18 month old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of lot-1 vaccines with a interval of 30 days for primary immunization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of lot-2 vaccines with a interval of 30 days for primary immunization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects aged 3 months receive 3 doses of lot-3 vaccines with a interval of 30 days for primary immunization</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>B1</arm_group_label>
    <arm_group_label>B3</arm_group_label>
    <arm_group_label>C1</arm_group_label>
    <arm_group_label>C2</arm_group_label>
    <arm_group_label>C3</arm_group_label>
    <other_name>DTacP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B2</arm_group_label>
    <other_name>DTaP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>A3</arm_group_label>
    <other_name>PENTAXIM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects aged 2months (60-89 days) and 3months (90-119 days) ；&#xD;
&#xD;
          -  Willing to provide proof of identity&#xD;
&#xD;
          -  Subjects aged 2 months have not been vaccinated with DTaP, IPV, Hib, or 13-valent&#xD;
             pneumococcal polysaccharide conjugate vaccine;&#xD;
&#xD;
          -  Subjects of 3 months have not been inoculated with DTaP vaccine, and IPV (only group&#xD;
             A3）；&#xD;
&#xD;
          -  Subjects'guardians or trustees are able to understand and sign the informed consent&#xD;
             voluntarily, comply with the requirements of the clinical study plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With temperature &gt;37.0°C on axillary setting before vacciation;&#xD;
&#xD;
          -  With a medical history of diphtheria, pertussis or tetanus;&#xD;
&#xD;
          -  Had contact with individuals with confirmed pertussis, diphtheria and tetanus diseases&#xD;
             in their families in the past 30 days;&#xD;
&#xD;
          -  Premature birth (delivery before the 37th week of pregnancy)or low birth weight (birth&#xD;
             weight&lt; &lt;2500g);&#xD;
&#xD;
          -  History of dystocia, suffocation rescue, neurological damage;&#xD;
&#xD;
          -  With congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc.&#xD;
&#xD;
          -  History of epilepsy, convulsions or convulsions, or have a family history of mental&#xD;
             illness;&#xD;
&#xD;
          -  History of abnormal blood coagulation (such as coagulation factor deficiency,&#xD;
             coagulopathy);&#xD;
&#xD;
          -  Had received immune enhancement or inhibitor therapy (continuous oral or instillation&#xD;
             for more than 14 days);&#xD;
&#xD;
          -  History of severe allergic reactions to vaccination, such as difficulty breathing,&#xD;
             urticaria;&#xD;
&#xD;
          -  Any prior administration of blood products in last 3 month;&#xD;
&#xD;
          -  Any prior administration of attenuated live vaccine in last 14 days;&#xD;
&#xD;
          -  Any prior administration of subunit or inactivated vaccines in last 7 days;&#xD;
&#xD;
          -  Plans to participate in or is participating in any other drug clinical study;&#xD;
&#xD;
          -  Has any other factors judged by investigators that make them unfit to participate in&#xD;
             the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengli Xia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengli Xia, BA</last_name>
    <phone>+8613592610137</phone>
    <email>xiasl@hncdc.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neihuang County Center for Disease Control and Prevention</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>456300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueqiang Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wen County Center for Disease Control and Prevention</name>
      <address>
        <city>Jiaozuo</city>
        <state>Henan</state>
        <zip>454850</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanbo Gen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuyang County Center for Disease Control and Prevention</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <zip>462400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yanjin County Center for Disease Control and Prevention</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangjie Zhu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to maintain the rights of the subject, do not open the IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

